“Efficacy and Safety of Biosimilar Cetuximab (CETUXA) in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Retrospective Multicenter Analysis.”. 2025. Journal of Carcinogenesis 24 (10s): 382-89. https://doi.org/10.64149/J.Carcinog.24.10s.382-389.